Concepedia

Indira Brar

IB

Statistics

Publications

28

Citations

3.1K

H-Index

21

Active since

2003

Affiliations

Henry Ford Hospital(Current)

Gilead Sciences (United States)

Henry Ford Health System

University of North Carolina at Chapel Hill

University College London

Indira Brar is an author at Henry Ford Hospital specializing in antiretroviral therapy, antiviral therapy, and pharmacotherapy.

ORCID

Publications per year

2003–2024

28

Publications

28

Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19

Samia Arshad, Paul E. Kilgore, Zohra Chaudhry et al. · International Journal of Infectious Diseases · 2020 · 566 citations · Full text

, , +9

Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19

Raef Fadel, Austin Morrison, Amit Vahia et al. · Clinical Infectious Diseases · 2020 · 441 citations · Full text

, , +17

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

Joel E. Gallant, Adriano Lazzarin, Anthony Mills et al. · The Lancet · 2017 · 380 citations

, , +15

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Anthony Mills, José Ramón Arribas, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2015 · 304 citations

, , +17

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy

Paul E. Sax, Andrew Zolopa, Indira Brar et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 206 citations

, , +17

1–5 of 28